{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:26:09Z","timestamp":1787030769194,"version":"build-2736575974"},"reference-count":26,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025,3,28]]},"DOI":"10.3960\/jslrt.24049","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T18:08:24Z","timestamp":1743098904000},"page":"17-27","source":"Crossref","is-referenced-by-count":1,"title":["Real-world use of BTK inhibitors for chronic lymphocytic leukemia in Japan: A retrospective observational database study"],"prefix":"10.3960","volume":"65","author":[{"given":"Momoko","family":"Nishikori","sequence":"first","affiliation":[{"name":"Department of Hematology, Kyoto University Hospital, Kyoto, Japan,"},{"name":"Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nozaki","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hayashi","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Arita","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Iwao","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2007; 64: 234-246.","DOI":"10.1016\/j.critrevonc.2007.04.008"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Ou Y, Long Y, Ji L <i>et al.<\/i> Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study. Front Oncol. 2022; 12: 840616.","DOI":"10.3389\/fonc.2022.840616"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Chihara D, Ito H, Matsuda T <i>et al.<\/i> Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014; 164: 536-545.","DOI":"10.1111\/bjh.12659"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Hallek M, Cheson BD, Catovsky D <i>et al.<\/i> iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131: 2745-2760.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Takizawa J, Izutsu K, Nagai H <i>et al.<\/i> Real world treatment practices for chronic lymphocytic leukemia in Japan: an observational database research study (CLIMBER-DBR). J Clin Exp Hematop. 2021; 61: 126-134.","DOI":"10.3960\/jslrt.20044"},{"key":"6","unstructured":"6 Japanese Society of Hematology. JSH practical guidelines for hematological malignancies, 2018, Chapter I Leukemia. 5 Chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Available at: http:\/\/www.jshem.or.jp\/gui-hemali\/table.html. Accessed 13 March 2025 [in Japanese]."},{"key":"7","unstructured":"7 Japanese Society of Hematology. Practical Guidelines for Hematological Malignancies, 2018. Revised Version April 2020, Tokyo, Kanehara &amp; Co., Ltd. 2020; pp. 121-128."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Eichhorst B, Robak T, Montserrat E <i>et al.<\/i> Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32: 23-33.","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020; 60: 130-137.","DOI":"10.3960\/jslrt.20002"},{"key":"10","unstructured":"10 Sharman JP, Black-Shinn JL, Clark J, Bitman B. Understanding ibrutinib treatment discontinuation patterns for chronic lymphocytic leukemia [abstract]. Blood. 2017; 130: 4060."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Hampel PJ, Ding W, Call TG <i>et al.<\/i> Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019; 60: 2712-2719.","DOI":"10.1080\/10428194.2019.1602268"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Parikh SA, Achenbach SJ, Call TG <i>et al.<\/i> The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020; 9: 3390-3399.","DOI":"10.1002\/cam4.2998"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Burger JA, Tedeschi A, Barr PM <i>et al.<\/i> Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373: 2425-2437.","DOI":"10.1056\/NEJMoa1509388"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Byrd JC, Brown JR, O\u2019Brien S <i>et al.<\/i> Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213-223.","DOI":"10.1056\/NEJMoa1400376"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Frei CR, Le H, McHugh D <i>et al.<\/i> Treatment patterns and outcomes of 1205 patients on novel agents in the US Veterans Health Administration (VHA) System: results from the largest retrospective EMR and chart review study in the real-world setting [abstract]. Blood. 2019; 134: 795.","DOI":"10.1182\/blood-2019-122434"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Hardy-Abeloos C, Pinotti R, Gabrilove J. Ibrutinib dose modifications in the management of CLL. J Hematol Oncol. 2020; 13: 66.","DOI":"10.1186\/s13045-020-00870-w"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Dimou M, Iliakis T, Pardalis V <i>et al.<\/i> Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leuk Lymphoma. 2019; 60: 2939-2945.","DOI":"10.1080\/10428194.2019.1620944"},{"key":"18","unstructured":"18 Imbruvica [package insert]. Pharmacyclics, Janssen Biotech, Inc, PA, USA (2020). Available at: https:\/\/www.rxabbvie.com\/pdf\/imbruvica_pi.pdf. Accessed 27 June 2024."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Arruga F, Gyau BB, Iannello A <i>et al.<\/i> Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020; 21: 1825.","DOI":"10.3390\/ijms21051825"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Tamura K, Sawada H, Izumi Y <i>et al.<\/i> Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001; 67: 152-157.","DOI":"10.1034\/j.1600-0609.2001.5790514.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Huntington SF, de Nigris E, Puckett J <i>et al.<\/i> Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Leuk Lymphoma. 2023; 64: 2286-2295.","DOI":"10.1080\/10428194.2023.2256911"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Maddocks KJ, Ruppert AS, Lozanski G <i>et al.<\/i> Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015; 1: 80-87.","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Tedeschi A, Frustaci AM, Mauro FR <i>et al.<\/i> Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? Blood Adv. 2021; 5: 5490-5500.","DOI":"10.1182\/bloodadvances.2021004824"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Burger JA, Barr PM, Robak T <i>et al.<\/i> Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020; 34: 787-798.","DOI":"10.1038\/s41375-019-0602-x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Barr PM, Owen C, Robak T <i>et al.<\/i> Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022; 6: 3440-3450.","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Ghosh N, Sharman JP, Gutierrez M <i>et al.<\/i> Real-world treatment patterns and outcomes by line of therapy and race in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma treated in the United States: results from the final analysis of the prospective, observational, informCLL registry. Clin Lymphoma Myeloma Leuk. 2024; 24: e301-e313.","DOI":"10.1016\/j.clml.2024.05.009"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24049\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:46:01Z","timestamp":1743209161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24049\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24049","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"24049"}}